Egetis Therapeutics AB is a Swedish pharmaceutical development company based in Stockholm. Egetis Therapeutics is an innovative, unique and integrated drug development company, focused on projects in late clinical development in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Emcitate is a drug candidate being developed as a potentially first-line treatment for patients with MCT8 deficiency, a rare disease with a high medical need and no available treatment.
Wikipedia